Menu
/REGISTER
PPB
Montecito
ROAM
Loading...
You are here:  Home  >  Health Care  -  Page 50

Montecito Bank & Trust
Latest

Amgen reacquires rights to sell 3 drugs worldwide

By   /  Monday, December 14th, 2015  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Amgen reacquires rights to sell 3 drugs worldwide

Amgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →

Read More →
Latest

Camarillo hospital getting $80 million upgrade

By   /  Friday, December 11th, 2015  /  Health Care, Latest news, Top Stories, West Ventura County  /  Comments Off on Camarillo hospital getting $80 million upgrade

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Novartis biosimilar works as well as Amgen’s Neulasta

By   /  Monday, December 7th, 2015  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Novartis biosimilar works as well as Amgen’s Neulasta

Swiss pharmaceutical Novartis announced Monday that a copycat version of Amgen’s Neulasta works just as well to prevent a condition that can lead to infection in women with breast cancer. Neulasta stimulates white blood cell production in the body, which helps the body fight cancer. Novartis’ new drug is part of a new class of Read More →

Read More →
Latest

Amgen seeks European OK of biosimilar drug, partners with Merck on studies

By   /  Friday, December 4th, 2015  /  East Ventura County, Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies

Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →

Read More →
Latest

Amgen bipolar about biosimilars

By   /  Friday, December 4th, 2015  /  Health Care, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen bipolar about biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Diabetes drug may be game changer

By   /  Friday, November 27th, 2015  /  Health Care, Latest news, Top Stories  /  Comments Off on Diabetes drug may be game changer

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen asks FDA to approve biosimilar drug

By   /  Wednesday, November 25th, 2015  /  Health Care, Latest news, Top Stories  /  Comments Off on Amgen asks FDA to approve biosimilar drug

Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →

Read More →